Results 171 to 180 of about 590,194 (288)

Quantifying Stated Preferences for Meningococcal Vaccines Among Adolescents/Young Adults and Parents of Adolescents in the United States: A Discrete Choice Experiment

Infectious Diseases and Therapy
Introduction Invasive meningococcal disease (IMD) is a severe and life-threatening disease. In the United States (US), vaccine coverage with MenACWY and MenB meningococcal vaccines is suboptimal among adolescents/young adults aged 16–23 years. A combined
Shahina Begum, Eliazar Sabater Cabrera, Oscar Herrera Restrepo, Cindy Burman, Woo-Yun Sohn, Elise Kuylen, Hiral Shah, Zeki Kocaata   +7 more
doaj   +1 more source

Association of Group B Meningococcal Vaccine Receipt With Reduced Gonorrhea Incidence Among University Students.

JAMA Netw Open, 2023
Robison SG, Leman RF.
europepmc   +1 more source

Safety, Reactogenicity, and Immunogenicity of a Tetravalent Meningococcal Polysaccharide–Diphtheria Toxoid Conjugate Vaccine Given to Healthy Adults [PDF]

, 2002
James Campbell, Robert Edelman, James C. King, Thomas Papa, Robert Ryall, Margaret B. Rennels   +5 more
openalex   +1 more source

Meningococcal Disease among United States Military Service Members in Relation to Routine Uses of Vaccines with Different Serogroup‐Specific Components, 1964–1998 [PDF]

, 2002
John F. Brundage, Margaret A. K. Ryan, Brian H. Feighner, Frederick Erdtmann   +3 more
openalex   +1 more source

A Glycoconjugate Vaccine forNeisseria meningitidisInduces Antibodies in Human Infants That Afford Protection against Meningococcal Bacteremia in a Neonate Rat Challenge Model [PDF]

, 2002
Kenneth T. Mountzouros, Kelly A. Belanger, Alan Howell, Garvin S. Bixler, Dace V. Madore   +4 more
openalex   +1 more source

Meningococcal vaccine [PDF]

Paediatrics & Child Health, 2005
openaire   +2 more sources

Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease

International Journal of Infectious Diseases, 2019
Meningococcal serogroup B (MenB) has become the main cause of invasive meningococcal disease in industrialized countries in recent years. The diversity of MenB strains and poor immunogenicity of the MenB capsular polysaccharide have made vaccine ...
Philip S. Watson, Patricia L. Novy, Leonard R. Friedland   +2 more
doaj  

Active Hospital Based Surveillance for Meningococcal Vaccine Adverse Events after a Community Mass Immunization Program [PDF]

, 2002
W Vaudry, BE Lee, Adam Roth
openalex   +1 more source

NEW FORMULATIONS: Meningococcal C polysaccharide conjugate vaccine [PDF]

, 2002

openalex   +1 more source

Comparing HIV Vaccine Immunogenicity across Trials with Different Populations and Study Designs [PDF]

arXiv
Safe and effective preventive vaccines have the potential to help stem the HIV epidemic. The efficacy of such vaccines is typically measured in randomized, double-blind phase IIb/III trials and described as a reduction in newly acquired HIV infections. However, such trials are often expensive, time-consuming, and/or logistically challenging.
arxiv